Etrasimod

Last updated

Etrasimod
Etrasimod.svg
Skeletal formula of etrasimod
Clinical data
Trade names Velsipity
Other namesAPD334, APD-334
AHFS/Drugs.com Monograph
MedlinePlus a623050
License data
Pregnancy
category
Routes of
administration 		By mouth
Drug class Sphingosine-1-phosphate receptor modulator
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding 97.9%
Metabolism Liver (CYP2C8, 2C9, 3A4)
Elimination half-life 30 hours
Excretion Feces (82%), kidneys (5%)
Identifiers
  • 2-[(3R)-7-{[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy}-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
Formula C26H26F3NO3
Molar mass 457.493 g·mol−1
3D model (JSmol)
  • C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CC[C@@H]5CC(=O)O)C(F)(F)F
  • InChI=1S/C26H26F3NO3/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-23/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32)/t17-/m1/s1
  • Key:MVGWUTBTXDYMND-QGZVFWFLSA-N

Etrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis. [6] It is a selective sphingosine-1-phosphate (S1P) receptor modulator that modifies the activity of the immune system. [6] It is taken by mouth. [6]

Contents

The most common side effects include lymphopenia (low levels of lymphocytes) and headache. [8]

Etrasimod was discovered by Arena Pharmaceuticals, with subsequent development by Pfizer. [10] Etrasimod was approved for medical use in the United States in October 2023, [6] and in the European Union in February 2024. [8]

Medical uses

Etrasimod is used for the treatment of moderate to severe ulcerative colitis. [6] [8]

Mechanism of action

It works by causing T cells to become trapped in the lymph nodes, preventing them from entering the bloodstream, from where they would travel to other tissues in the body and mediate inflammation. [11] [12] [13] [14] [15] [16]

Society and culture

Velsipity was approved by the US Food and Drug Administration (FDA) in October 2023. [6] [17] [18]

In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Velsipity, intended for the treatment of ulcerative colitis. [8] The applicant for this medicinal product is Pfizer Europe MA EEIG. [8] Etrasimod was approved for medical use in the European Union in February 2024. [8]

Names

Etrasimod is the international nonproprietary name. [19]

References

  1. 1 2 "Velsipity (Etrasimod)". Therapeutic Goods Administration (TGA). 24 June 2024. Archived from the original on 7 July 2024. Retrieved 7 July 2024.
  2. ↑ "Velsipity (Pfizer Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 1 July 2024. Archived from the original on 7 July 2024. Retrieved 7 July 2024.
  3. ↑ "Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024". Federal Register of Legislation. 30 May 2024. Archived from the original on 10 June 2024. Retrieved 10 June 2024.
  4. ↑ "Regulatory Decision Summary for Velsipity". Health Canada . 31 January 2024. Archived from the original on 1 April 2024. Retrieved 1 April 2024.
  5. ↑ "Summary Basis of Decision for Velsipity". Health Canada . 21 August 2024. Retrieved 12 October 2024.
  6. 1 2 3 4 5 6 7 "Velsipity- etrasimod tablet, film coated". DailyMed. 16 November 2023. Archived from the original on 23 February 2024. Retrieved 23 February 2024.
  7. ↑ "Velsipity- etrasimod tablet, film coated". DailyMed. 17 November 2023. Archived from the original on 23 February 2024. Retrieved 23 February 2024.
  8. 1 2 3 4 5 6 7 "Velsipity EPAR". European Medicines Agency (EMA). 14 December 2023. Archived from the original on 15 December 2023. Retrieved 17 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  9. ↑ "Velsipity Product information". Union Register of medicinal products. 19 February 2024. Archived from the original on 23 February 2024. Retrieved 23 February 2024.
  10. ↑ Bayer M (2 May 2023). "Pfizer tosses newly acquired meds out of the Arena". Fierce Biotech. Archived from the original on 21 October 2023. Retrieved 13 October 2023.
  11. ↑ Atreya R, Neurath MF (April 2023). "The sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis". Lancet. 401 (10383): 1132–1133. doi:10.1016/S0140-6736(23)00228-3. PMID   36871570. S2CID   257286238.
  12. ↑ Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, et al. (April 2023). "Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies". Lancet. 401 (10383): 1159–1171. doi: 10.1016/S0140-6736(23)00061-2 . PMID   36871574. S2CID   257286271.
  13. ↑ Dal Buono A, Gabbiadini R, Alfarone L, Solitano V, Repici A, Vetrano S, et al. (July 2022). "Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine". Biomedicines. 10 (7): 1735. doi: 10.3390/biomedicines10071735 . PMC   9313037 . PMID   35885040.
  14. ↑ Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, et al. (April 2020). "Modulation of sphingosine-1-phosphate in ulcerative colitis". Expert Opinion on Biological Therapy. 20 (4): 413–420. doi:10.1080/14712598.2020.1732919. PMID   32093531. S2CID   211475181.
  15. ↑ Al-Shamma H, Lehmann-Bruinsma K, Carroll C, Solomon M, Komori HK, Peyrin-Biroulet L, et al. (June 2019). "The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis". The Journal of Pharmacology and Experimental Therapeutics. 369 (3): 311–317. doi: 10.1124/jpet.118.254268 . PMID   30872391. S2CID   78093401.
  16. ↑ Peyrin-Biroulet L, Christopher R, Behan D, Lassen C (May 2017). "Modulation of sphingosine-1-phosphate in inflammatory bowel disease". Autoimmunity Reviews. 16 (5): 495–503. doi:10.1016/j.autrev.2017.03.007. PMID   28279838.
  17. ↑ Brooks M (13 October 2023). "FDA Approves New Drug for Ulcerative Colitis". Medscape. Archived from the original on 21 October 2023. Retrieved 13 October 2023.
  18. ↑ "Velsipity (etrasimod) tablets for the treatment of moderately to severely active ulcerative colitis in adults" (PDF). Approval Letter. U.S. Food and Drug Administration. Archived from the original (PDF) on 7 July 2024. Retrieved 19 October 2023.
  19. ↑ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl: 10665/330961 .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.